Kuang-Chi Group, a Shenzhen, China-based technology conglomerate, has launched its Global Community of Innovation (GCI) Fund II and the opening of its Israel-based International Innovation Headquarters.
EasyStack, a Beijing, China-based OpenStack open source cloud enterprise, closed a $50m Series C funding.
Axiom Asia Private Capital closed its fourth fund, with US$ 1.028 billion in commitments from a select group of institutional limited partners.
Ascentage Pharma, a Hong Kong-based global, clinical-stage biopharmaceutical company focused on apoptosis-targeted oncology drug discovery and development, completed RMB 500m (approximately $72m) Series B financing.
e-Shang Redwood, a pan-Asia logistics real estate developer and operator, closed a US$300m pre-IPO equity investment.
Mobike, a Chinese bike-sharing startup, raised $215M in Series D funding.
Ascletis, a Hangzhou, China-based biotechnology company dedicated to discovering, developing and commercializing new treatments for liver diseases, completed a US$100m (RMB700m) Series B financing.
Babytree, a Beijing, China-based parenting website, raised 3 billion yuan ($437m) in equity financing.
Beijing-based Spearhead Integrated Marketing Communication Group (SZSE: 300071) has completed the acquisition of San Francisco-based Smaato Inc. and Smaato Holding AG, the independent global real-time advertising platform for mobile publishers and app developers, for $148m.
Yeahmobi, a Xi’an, China-based mobile performance marketing network, raised RMB ￥639 million (approx. $100m) in funding.
Vkansee, the NYC- and Shenzen, China-based creator of an under-glass and patented and ultra-thin optical fingerprint sensor, raised $10m in funding.
Warburg Pincus, a global private equity firm focused on growth investing, closed a $2 billion fund focused on China.
dMed Company Limited, a China-based clinical contract research organization, reportedly raised $8m in Series A funding.
Novogene Technology Co., Ltd., a Beijing, China-based commercial provider of genomic services and solutions with next-generation sequencing (NGS) and bioinformatics expertise, completed a $75M [RMB515M] Series B funding.
Innovent Biologics, Inc., a Shangai, China-based biopharmaceutical company dedicated to the discovery, development manufacturing, and commercialization of biologics, raised $260m in Series D financing.